Sanjanaa Senthilkumar

Ms. Sanjanaa Senthilkumar

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
EEEvrim Erdemogľu
Evrim Erdemogľu
SOStuart A. Ostby
Stuart A. Ostby
SSSanjanaa Senthilkumar
Sanjanaa Senthilkumar
Amanika KumarAmanika Kumar
Amanika Kumar
SVSujay A. Vora
Sujay A. Vora
KBKristina A Butler
Kristina A Butler
Objective: We aimed to analyze the current literature for IORT in gynecological cancers and summarized clinical outcomes regarding patient selection. Methods: A systematic search was conducted utilizing PUBMED, Embase, and CINAHL to identify studies following PRISMA-ScR guidelines. A PICOS structure was utilized: population: patients with epithelial gynecological cancers; intervention: IORT; C: a comparator was not required, as we aimed to analyze patient selection; outcome: clinical outcomes and overall survival; and S: experimental and quasi-experimental analytical observational studies and descriptive observational studies, excluding case series published in English and limited to the last 10 years. Data extraction was conducted for patient selection, IORT, oncological outcomes, and morbidity. Results: A total of 707 results were identified, and 509 studies were uploaded to Covidence for screening after removing duplications. Of the 21 eligible studies, 9 were included in the final review. The total number of patients included was 348. The studies were retrospective single-institution studies, except for one. There was significant heterogeneity in their design and protocols. IORT was exclusively used for recurrent and advanced stage gynecological cancers adjunct to pelvic exenteration or laterally extended endopelvic resections with variable indications across institutions. The mean number of IORT patients per study was 2.8 per year. Survival rates were variable and dependent on the surgical margin. Endometrial cancer had a favorable outcome compared to vulvar and cervical cancers. Conclusions: Current clinical practice, as demonstrated by the research, is consistent with NCCN guidelines that endorse the application of IORT in instances of recurrent cervical, vaginal, and vulvar malignancies; however, there are no established recommendations for primary tumors. The analysis shows that there are gaps in our knowledge, mainly regarding the status of the margins, the criteria used to choose patients, and the outcomes that are specific to each histology. The standardization of protocols and prospectively powered studies are needed to refine patient selection criteria.

7 January 2026 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
SSSanjanaa Senthilkumar
Sanjanaa Senthilkumar
RCRohit A Chitale
Rohit A Chitale
Prakasha KempaiahPrakasha Kempaiah
Prakasha Kempaiah
DSDeepika Saraf
Deepika Saraf
RDRavi Durvasula
Ravi Durvasula
: Cervical cancer is a malignancy with a well-established viral origin linked to high-risk human papillomavirus (HPV) types. Globally, there are 348,709 estimated deaths among 662,301 cervical cancer cases. India faces a disproportionately high burden, contributing to 79,906 of these deaths and accounting for over 22% of global deaths. The nation’s high mortality rate is attributable to the low rate of cervical cancer screening and HPV vaccination uptake. There is a greater impact of cervical cancer on those of lower socioeconomic status and a cultural stigma surrounding sexually transmitted infections. We recommend a comprehensive cervical cancer prevention strategy, including screening programs, culturally sensitive education for patients and providers, government-endorsed HPV vaccination, and continuing studies on diagnostics and vaccination in the Indian context.

1 March 2024 in The Natural Products Journal
Verified
Journal Article
Closed access
PDF file
SSSanjanaa Senthilkumar
Sanjanaa Senthilkumar
MSMegan E. Solan
Megan E. Solan
MFMaria T. Fernandez-Luna
Maria T. Fernandez-Luna
Ramon LavadoRamon Lavado
Ramon Lavado
Introduction: An increase in obesity-related diseases is becoming an alarming worldwide problem. Therefore, new therapeutic methods are constantly sought to prevent, treat, and alleviate symptoms of the diseases associated with obesity. Method: This study investigates the effects of two natural compounds (indole-3-carbinol, I3C, a bioactive indolic compound found in cruciferous vegetables; cannabidiol, CBD, the active ingredient derived from the hemp plant) on the fatty acid accumulation in the human liver cell line HepaRG, a well-established model for non-alcoholic fatty liver disease (NAFLD) and in human pre-adipocytes (adipose-derived mesenchymal stem cells, MSC). Results: EC50s of each compound were in the high µM range (approximately 30 mg/L), showing the low toxicity of these compounds. Determination of the selected compounds in cell media showed no significant differences during the exposure, suggesting that no significant metabolism or degradation happened during the exposure time. Quantification of the bioaccumulation of lipid droplets on exposed HepaRG revealed a significant reduction and mitigation of fatty acid accumulation when exposed to 1 nM of I3C and 100 nM of CBD.). On MSC cells a significant inhibition of lipogenesis and adipocyte differentiation was observed in cells exposed to 0.1 nM of I3C and 1 nM of CBD. Conclusion: This study provides a significant contribution to advancing the understanding of preventative dietary strategies that target adipocyte differentiation and NAFLD.

21 July 2026 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
SSSanjanaa Senthilkumar
Sanjanaa Senthilkumar
RMRyan McKenna
Ryan McKenna
NPNeema Patel
Neema Patel
ACAakriti R Carrubba
Aakriti R Carrubba

19 May 2024 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
SSSanjanaa Senthilkumar
Sanjanaa Senthilkumar
TMTara Morgan
Tara Morgan
MWMegan N. Wasson
Megan N. Wasson